TY - JOUR
T1 - Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness
T2 - A multi-institutional study of 1524 cases
AU - Mandalà, Mario
AU - Galli, Francesca
AU - Cattaneo, Laura
AU - Merelli, Barbara
AU - Rulli, Eliana
AU - Ribero, Simone
AU - Quaglino, Pietro
AU - De Giorgi, Vincenzo
AU - Pigozzo, Jacopo
AU - Sileni, Vanna Chiarion
AU - Chirco, Alessandra
AU - Ferrucci, Pier Francesco
AU - Occelli, Marcella
AU - Imberti, Gianlorenzo
AU - Piazzalunga, Dario
AU - Massi, Daniela
AU - Tondini, Carlo
AU - Queirolo, Paola
PY - 2016
Y1 - 2016
N2 - Background: The 7th edition of the TNM American Joint Committee on Cancer classification incorporates mitotic rate (MR) only for primary cutaneous melanoma (PCM) with Breslow thickness (BT) ≤1 mm. Objective: To investigate whether and to what extent MR is able to predict sentinel lymph node (SLN) status and clinical outcome of PCM patients with BT >1 mm. Methods: The study included consecutive patients with PCM. Logistic regression and Cox regression model were used to analyze the impact of MR on SLN status, disease-free survival (DFS), and overall survival. Results: From 1998 to 2015, 1524 PCM (median age 57.8 years) cases were diagnosed with a BT >1 mm in six centers of the Italian Melanoma Intergroup. Median follow-up was 5.0 years. By multivariate analysis, MR was associated with SLN positivity (odds ratio 1.98, 95% confidence interval [CI] 1.12-3.50, . P = .018). After adjusting for BT, ulceration, age, sex, and SLN status, MR correlated with a poor DFS (hazard ratio 1.52, 95% CI 1.18-1.97, . P = .002) and overall survival (hazard ratio 1.63, 95% CI 1.17-2.29, . P = .004). Limitations: Retrospective analysis. Conclusion: MR is an independent prognostic factor for PCM patients with BT >1 mm. Incorporating this tissue biomarker could provide a better stratification of patients entering clinical trials in the adjuvant setting.
AB - Background: The 7th edition of the TNM American Joint Committee on Cancer classification incorporates mitotic rate (MR) only for primary cutaneous melanoma (PCM) with Breslow thickness (BT) ≤1 mm. Objective: To investigate whether and to what extent MR is able to predict sentinel lymph node (SLN) status and clinical outcome of PCM patients with BT >1 mm. Methods: The study included consecutive patients with PCM. Logistic regression and Cox regression model were used to analyze the impact of MR on SLN status, disease-free survival (DFS), and overall survival. Results: From 1998 to 2015, 1524 PCM (median age 57.8 years) cases were diagnosed with a BT >1 mm in six centers of the Italian Melanoma Intergroup. Median follow-up was 5.0 years. By multivariate analysis, MR was associated with SLN positivity (odds ratio 1.98, 95% confidence interval [CI] 1.12-3.50, . P = .018). After adjusting for BT, ulceration, age, sex, and SLN status, MR correlated with a poor DFS (hazard ratio 1.52, 95% CI 1.18-1.97, . P = .002) and overall survival (hazard ratio 1.63, 95% CI 1.17-2.29, . P = .004). Limitations: Retrospective analysis. Conclusion: MR is an independent prognostic factor for PCM patients with BT >1 mm. Incorporating this tissue biomarker could provide a better stratification of patients entering clinical trials in the adjuvant setting.
KW - Cutaneous melanoma
KW - Disease-free survival
KW - Mitotic rate
KW - Outcome
KW - Overall survival
KW - Prognosis
KW - Sentinel lymph node
UR - http://www.scopus.com/inward/record.url?scp=85006747010&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85006747010&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2016.08.066
DO - 10.1016/j.jaad.2016.08.066
M3 - Article
AN - SCOPUS:85006747010
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
SN - 0190-9622
ER -